Company Page

OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus platform to orchestrate an immune response and treat cancer. The company's multi-armed myxoma virus delivers multiple antitumor immunomodulatory proteins targeting critical points in the cancer immunity cycle to modulate the tumor microenvironment and stimulate robust anti-tumor responses against solid tumors and hematologic cancers.

Company Founded in 2018

Healthtech & Biotech